Physician profile
Crystal Mcmanus
NPI 1689240426
$784.90
in general payments reported to CMS, 2019-2025
15 companies · $696 in 2025
The $696 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.17 · 2022: $50.76 · 2023: $20.52 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.94 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $104.00 | 2025 | Trintellix |
| Neurocrine Biosciences, INC. | $97.85 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $89.70 | 2022-2025 | Rexulti |
| Alkermes, INC. | $65.05 | 2025 | Aristada, Lybalvi |
| Abbvie INC. | $48.88 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $46.15 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $36.91 | 2025 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $35.81 | 2022-2023 | Spravato |
| Lundbeck LLC | $24.38 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $21.79 | 2025 | Sunosi |
| Ucb, INC. | $20.75 | 2022 | |
| Corium, LLC | $19.77 | 2025 | Azstarys |
| Noven Therapeutics, LLC | $18.75 | 2025 | Xelstrym |
| Greenwich Biosciences, INC. | $17.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.